We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » IP Think Tank Cautions Against Breaking Gilead’s Truvada Patent
IP Think Tank Cautions Against Breaking Gilead’s Truvada Patent
As HIV patient advocates urge the federal government to “break” drug patents in an effort to lower the prices of HIV drugs, an intellectual property think tank cautioned that the tactic could backfire.